Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Capivasertib

FDA-approved product (tablet, oral), marketed as Truqap.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Capivasertib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Breast cancer
  • Breast neoplasm
  • Cancer
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Other protein kinase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA53.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli44.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae37.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis53.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Capivasertib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Capivasertib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.

    NCT03616587 · start 2018-10-11

    Registered record
    Registry ID
    NCT03616587
    Conditions
    ER+ HER2- Advanced Breast Cancer
    Interventions
    AZD9833; AZD9833; AZD9833 with palbociclib; AZD9833 with palbociclib; AZD9833 with everolimus; AZD9833 with everolimus; AZD9833 with abemaciclib; AZD9833 with abemaciclib; AZD9833 with capivasertib; AZD9833 with capivasertib; AZD9833 with ribociclib; AZD9833 with ribociclib; AZD9833 with anastrozole; AZD9833 with anastrozole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2018-10-11
    Completion
    2027-06-24
    Enrolment
    396

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionER+ HER2- Advanced Breast Cancer
    InterventionAZD9833; AZD9833; AZD9833 with palbociclib; AZD9833 with palbociclib +10 more
    PhasePhase 1
    Registry statusActive not recruiting

  • Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

    NCT03660826 · start 2018-09-27

    Registered record
    Registry ID
    NCT03660826
    Conditions
    Endometrial Adenocarcinoma; Endometrial Mixed Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Endometrioid Adenocarcinoma; Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
    Interventions
    Biospecimen Collection; Bone Marrow Aspirate; Bone Marrow Biopsy; Capivasertib; Cediranib Maleate; Computed Tomography; Durvalumab; Echocardiography Test; Multigated Acquisition Scan; Olaparib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2018-09-27
    Completion
    2027-07-01
    Enrolment
    288

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometrial Adenocarcinoma; Endometrial Mixed Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma +2 more
    InterventionBiospecimen Collection; Bone Marrow Aspirate; Bone Marrow Biopsy; Capivasertib +6 more
    PhasePhase 2
    Registry statusActive not recruiting

  • AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations

    NCT03310541 · start 2017-10-11

    Registered record
    Registry ID
    NCT03310541
    Conditions
    Breast Cancer; Prostate Cancer; Advanced Solid Tumors
    Interventions
    AZD5363; Enzalutamide; Fulvestrant
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-10-11
    Completion
    2023-05-03
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Prostate Cancer; Advanced Solid Tumors
    InterventionAZD5363; Enzalutamide; Fulvestrant
    PhasePhase 1
    Registry statusCompleted

  • The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) Trial

    NCT03182634 · start 2016-12-15

    Registered record
    Registry ID
    NCT03182634
    Conditions
    Advanced Breast Cancer
    Interventions
    Fulvestrant; Neratinib; AZD5363; Olaparib; AZD6738
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2016-12-15
    Completion
    2023-11
    Enrolment
    1,150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Breast Cancer
    InterventionFulvestrant; Neratinib; AZD5363; Olaparib +1 more
    PhasePhase 2
    Registry statusUnknown

  • Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)

    NCT04439123 · start 2016-05-31

    Registered record
    Registry ID
    NCT04439123
    Conditions
    Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Hematopoietic and Lymphoid Cell Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Multiple Myeloma
    Interventions
    Capivasertib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2016-05-31
    Completion
    2027-03-31
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Lymphoma; Advanced Malignant Solid Neoplasm; Hematopoietic and Lymphoid Cell Neoplasm; Refractory Lymphoma +2 more
    InterventionCapivasertib
    PhasePhase 2
    Registry statusActive not recruiting

  • OLAParib COmbinations

    NCT02576444 · start 2015-11

    Registered record
    Registry ID
    NCT02576444
    Conditions
    Cancer
    Interventions
    AZD2281; AZD5363; AZD1775; AZD6738
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2015-11
    Completion
    2019-11-18
    Enrolment
    67

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer
    InterventionAZD2281; AZD5363; AZD1775; AZD6738
    PhasePhase 2
    Registry statusTerminated

  • Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

    NCT02465060 · start 2015-08-17

    Registered record
    Registry ID
    NCT02465060
    Conditions
    Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma; Breast Carcinoma; Cervical Carcinoma; Colon Carcinoma; Colorectal Carcinoma; Endometrial Carcinoma; Esophageal Carcinoma; Exocrine Pancreas Carcinoma; Gastric Carcinoma; Glioma; Head and Neck Carcinoma; Hematopoietic and Lymphoid Cell Neoplasm; Kidney Carcinoma; Liver Carcinoma; Lung Carcinoma; Lymphoma; Malignant Uterine Corpus Neoplasm; Malignant Uterine Neoplasm; Melanoma; Multiple Myeloma; Ovarian Carcinoma; Prostate Carcinoma; Rectal Carcinoma; Recurrent Bladder Carcinoma; Recurrent Breast Carcinoma; Recurrent Cervical Carcinoma; Recurrent Colon Carcinoma; Recurrent Colorectal Carcinoma; Recurrent Esophageal Carcinoma; Recurrent Gastric Carcinoma; Recurrent Glioma; Recurrent Head and Neck Carcinoma; Recurrent Liver Carcinoma; Recurrent Lung Carcinoma; Recurrent Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Malignant Uterine Corpus Neoplasm; Recurrent Melanoma; Recurrent Multiple Myeloma; Recurrent O
    Interventions
    Adavosertib; Afatinib; Afatinib Dimaleate; Binimetinib; Biopsy Procedure; Biospecimen Collection; Capivasertib; Computed Tomography; Copanlisib; Copanlisib Hydrochloride; Crizotinib; Cytology Specimen Collection Procedure; Dabrafenib; Dabrafenib Mesylate; Dasatinib; Defactinib; Defactinib Hydrochloride; Echocardiography Test; Erdafitinib; Fexagratinib; Ipatasertib; Laboratory Biomarker Analysis; Larotrectinib; Larotrectinib Sulfate; Magnetic Resonance Imaging; Multigated Acquisition Scan; Nivolumab; Osimertinib; Palbociclib; Pertuzumab; PI3K-beta Inhibitor GSK2636771; Radiologic Examination; Radionuclide Imaging; Relatlimab; Sapanisertib; Sunitinib Malate; Taselisib; Trametinib; Trastuzumab; Trastuzumab Emtansine; Ulixertinib; Vismodegib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2015-08-17
    Completion
    2026-12-31
    Enrolment
    6,452

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma; Breast Carcinoma +38 more
    InterventionAdavosertib; Afatinib; Afatinib Dimaleate; Binimetinib +38 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Trial of AZD5363 Plus Paclitaxel /AZD2014 Plus Paclitaxel in Biomarker Negative (PIK3CA/MEK/RAS/TP53/MET) Gastric Adenocarcinoma Patients as Second-line Chemotherapy

    NCT02449655 · start 2015-02-12

    Registered record
    Registry ID
    NCT02449655
    Conditions
    Advanced Gastric Adenocarcinoma
    Interventions
    AZD5363; paclitaxel; AZD2014; paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2015-02-12
    Completion
    2018-07-16
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Gastric Adenocarcinoma
    InterventionAZD5363; paclitaxel; AZD2014; paclitaxel
    PhasePhase 2
    Registry statusTerminated

  • Study of AZD5363 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring PIK3CA Mutation and/or PIK3CA Amplification as a Second-line Chemotherapy

    NCT02451956 · start 2015-01-07

    Registered record
    Registry ID
    NCT02451956
    Conditions
    Advanced Gastric Cancer
    Interventions
    AZD5363; paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-01-07
    Completion
    2019-05-24
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Gastric Cancer
    InterventionAZD5363; paclitaxel
    PhasePhase 2
    Registry statusCompleted

  • A Study of Enzalutamide in Combination With AZD5363 in Patients With mCRPC

    NCT02525068 · start 2014-12

    Registered record
    Registry ID
    NCT02525068
    Conditions
    Adenocarcinoma of the Prostate
    Interventions
    AZD5363; Enzalutamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2014-12
    Completion
    2020-03
    Enrolment
    136

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdenocarcinoma of the Prostate
    InterventionAZD5363; Enzalutamide
    PhasePhase 2
    Registry statusUnknown

  • mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

    NCT02208375 · start 2014-11-11

    Registered record
    Registry ID
    NCT02208375
    Conditions
    BRCA1 Mutation Carrier; BRCA2 Mutation Carrier; Endometrial Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; High Grade Ovarian Serous Adenocarcinoma; Progesterone Receptor Negative; Recurrent Breast Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage III Uterine Corpus Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7; Stage IV Uterine Corpus Cancer AJCC v7; Triple-Negative Breast Carcinoma
    Interventions
    Capivasertib; Laboratory Biomarker Analysis; Olaparib; Pharmacological Study; Vistusertib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2014-11-11
    Completion
    2028-06-30
    Enrolment
    159

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBRCA1 Mutation Carrier; BRCA2 Mutation Carrier; Endometrial Adenocarcinoma; Estrogen Receptor Negative +12 more
    InterventionCapivasertib; Laboratory Biomarker Analysis; Olaparib; Pharmacological Study +1 more
    PhasePhase 1
    Registry statusActive not recruiting

  • PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer

    NCT02423603 · start 2014-05-14

    Registered record
    Registry ID
    NCT02423603
    Conditions
    Metastatic Breast Cancer
    Interventions
    Paclitaxel; AZD5363; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-05-14
    Completion
    2024-06-30
    Enrolment
    71

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Breast Cancer
    InterventionPaclitaxel; AZD5363; Placebo
    PhasePhase 2
    Registry statusCompleted

  • SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients

    NCT02117167 · start 2014-04-23

    Registered record
    Registry ID
    NCT02117167
    Conditions
    Non-small Cell Lung Cancer Metastatic
    Interventions
    AZD2014; AZD4547; AZD5363; AZD8931; Selumetinib; Vandetanib; Standard maintenance for squamous NSCLC; Pemetrexed; Durvalumab; savolitinib; Olaparib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-04-23
    Completion
    2023-12
    Enrolment
    999

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-small Cell Lung Cancer Metastatic
    InterventionAZD2014; AZD4547; AZD5363; AZD8931 +7 more
    PhasePhase 2
    Registry statusCompleted

  • SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer

    NCT02299999 · start 2014-04-07

    Registered record
    Registry ID
    NCT02299999
    Conditions
    Metastatic Breast Cancer
    Interventions
    AZD2014; AZD4547; AZD5363; AZD8931; Selumetinib; Vandetanib; Bicalutamide; Olaparib; Anthracyclines; Taxanes; cyclophosphamide; DNA intercalators; Methotrexate; vinca alkaloids; Platinum based chemotherapies; Bevacizumab; Mitomycin C; Eribulin; MEDI4736
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2014-04-07
    Completion
    2025-12
    Enrolment
    1,460

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Breast Cancer
    InterventionAZD2014; AZD4547; AZD5363; AZD8931 +15 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Trial of Olaparib in Combination With AZD5363 (ComPAKT)

    NCT02338622 · start 2014-03-31

    Registered record
    Registry ID
    NCT02338622
    Conditions
    Advanced Cancer
    Interventions
    olaparib; AZD5363
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-03-31
    Completion
    2017-03-21
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Cancer
    Interventionolaparib; AZD5363
    PhasePhase 1
    Registry statusCompleted